Lexeo Therapeutics (LXEO) reported positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia cardiomyopathy. In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine
investigator-initiated Phase 1A trial, treatment with LX2006 was associated with clinically significant improvements in cardiac biomarkers and functional measures, and increased frataxin protein expression was observed in all participants with cardiac biopsies.
"We believe these data show LX2006 exceeding the thresholds aligned with the U.S. Food and Drug Administration to support accelerated approval in the planned registrational study, said Sandi See Tai, Chief Development Officer at Lexeo.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com